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The central role played by the ERK/MAPK pathway downstream of RAS in human
neoplasias is best exemplified in the context of melanoma skin cancer. Signaling through
theMAPK pathway is crucial for the proliferation of melanocytes, the healthy pigment cells
that give rise to melanoma. However, hyper-activation of the MAPK-pathway is found in
over 90% of melanomas with approximately 50% of all patients displaying mutations
in the kinase BRAF, and approximately 28% of all patients harboring mutations in the
MAPK-pathway up-stream regulator NRAS. This finding has led to the development
of BRAF and MEK inhibitors whose application in the clinic has shown unprecedented
survival responses. Unfortunately the responses toMAPK pathway inhibitors are transient
with most patients progressing within a year and a median progression free survival of
7–10 months. The disease progression is due to the development of drug-resistance
based on various mechanisms, many of them involving a rewiring of the MAPK pathway.
In this article we will review the complexity of MAPK signaling in melanocytic cells as well
as the mechanisms of action of different MAPK-pathway inhibitors and their correlation
with clinical response. We will reflect on mechanisms of innate and acquired resistance
that limit patient’s response, with a focus on the MAPK signaling network. Because of
the resurgence of antibody-based immune-therapies there is a growing feeling of failure
in the targeted therapy camp. However, recent studies have revealed new windows of
therapeutic opportunity for melanoma sufferers treated with drugs targeting the MAPK
pathway, and these opportunities will be discussed.
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THE ERK/MAP-KINASE PATHWAY IS A CRUCIAL REGULATOR OF
MELANOCYTE PROLIFERATION AND DIFFERENTIATION
Cutaneous melanoma originates from melanocytes, neural-crest derived pigment-producing cells
located in the epidermis, where their major function is to protect keratinocytes from UV-induced
DNA damage (Abdel-Malek et al., 2010). Under basal conditions and in response to UV the
physiology of a melanocyte is modulated by keratinocytes, which secret specific paracrine acting
factors (Hirobe, 2011). These secreted factors stimulate a broad spectrum of intracellular signaling.
However, a crucial downstream event triggered by almost all of the extracellular factors is the
activation of the ERK/MAP-kinase (MAPK)-pathway, which plays a major role in coordinating
the balance between melanocyte differentiation and proliferation (see Figure 1A).
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Up-regulation of intracellular cAMP levels, which induces the
differentiation process (Busca and Ballotti, 2000), triggers a very
transient (≤ 60min) and weak activation of ERK (Wellbrock
et al., 2002b). On the other hand, activation of the MAPK-
pathway by the synergistic action of factors like SCF, FGF, or
HGF stimulates strong sustained ERK activation, which triggers
melanocyte proliferation (Bohm et al., 1995).
At the center of this transient vs. sustained ERK activation
is MITF (Figure 1A), a tissue specific bHLH-Zip transcription
factor and fate regulator of the melanocyte lineage, which
is a target of ERK phosphorylation (Hemesath et al., 1998;
Figure 1A). MITF regulates the expression of genes controlling
differentiation (e.g., TYR) proliferation (e.g., CDK2) and survival
(e.g., BCL2, BCL2A1) (Wellbrock and Arozarena, 2015). As ERK
phosphorylation can increase MITF’s transcriptional activity
toward TYR (Hemesath et al., 1998), transient ERK activation can
favor differentiation, and in the context of cAMP signaling this is
paralleled by a strong transcriptional up-regulation of the MITF
transcript (Price et al., 1998). However, ERK phosphorylation can
also trigger ubiquitin-mediated degradation (Wu et al., 2000),
and as a result of sustained ERK activation MITF protein levels
are reduced, a situation that is compatible with proliferation
(Wellbrock and Marais, 2005). Nevertheless, because MITF is
crucial for cell survival, its expression in proliferative cells is
ensured through the ERK induced transcription factor BRN2
(Wellbrock et al., 2008). In summary, the MAPK-pathway has
stringent control over the melanocyte/melanoma fate-decision
regulator MITF, which might explain why this pathway is so
particularly critical in the biology of a melanocytic cell and hence
in melanoma.
THE DISCOVERY OF THE RELEVANCE OF
ERK/MAP-KINASE SIGNALING FOR
MELANOMA
Melanoma is not one of the cancers with the highest incidences
when compared to breast, lung or colon cancer and therefore
historically not much attention was given to the research directed
toward a better understanding of this skin cancer. However,
this changed dramatically in 2002, when the Cancer Genome
Project/Sanger Institute identified oncogenic mutations in the
MEK-upstream kinase BRAF in over 50% of melanoma (Davies
et al., 2002). This discovery led to an explosion in published
work on the relevance of the MAPK-pathway in melanoma; as
such research into melanoma can be divided in the pre- and
post-2002 era.
The development of theMEK inhibitors PD908059 andU0126
in the pre-2002 era resulted in the first studies demonstrating
a role for MEK in human melanoma cell proliferation,
survival and invasion (Kortylewski et al., 2001; Li et al.,
2001). The first indication for an in vivo relevance of MAPK
signaling in this disease came however from Xiphophorus,
a genetically controlled vertebrate model for melanoma first
described in 1928 (Wellbrock et al., 2002a). In these animals
strong constitutive MAPK activation occurs already in benign
nevus-like lesions (Wellbrock and Schartl, 1999), suggesting an
involvement of MAPK-signaling in the early steps of pigment-
cell transformation (Figure 1B). In 2002, Cohen et al. reported
constitutive ERK-phosphorylation in >20% of benign nevi
and>80% of primarymelanoma, and hence confirmed activation
of MAPK-signaling as an early event in human melanoma
development (Cohen et al., 2002).
Since the first description of BRAF mutations in melanoma
(Davies et al., 2002) BRAFV600E, the most predominant mutant,
has been shown to constitutively activate ERK in melanocytes,
and to transform p16/INK4A deficient melanocytes (Wellbrock
et al., 2004). BRAFV600E induces melanoma in mice, where this
can be accelerated by the absence of p16/INK4A or the PI3K-
antagonist PTEN, or by UV exposure (Dankort et al., 2009;
Dhomen et al., 2009; Viros et al., 2014). In line with what has
been observed in humans, in zebrafish BRAFV600E only triggers
the formation of benign nevi (Patton et al., 2005). However,
in zebrafish mutants where a temperature shift lowers levels
of functional MITF (possibly compatible with proliferation),
BRAFV600E efficiently induces melanoma (Lister et al., 2014;
Zeng et al., 2015). This further emphasizes the relevance of the
BRAF/MITF connection for melanoma development.
In humans, BRAFV600E mutations are found in benign
nevi (Pollock et al., 2003), clonal populations of senescent
melanocytes (Gray-Schopfer et al., 2006). BRAFV600E
can stimulate senescence in human melanocytes in vitro
(Michaloglou et al., 2005). Hence, nevi might represent the result
of oncogene-induced senescence. Nevertheless, formation of a
nevus requires an initial pulse of melanocyte proliferation, and
MAPK signaling appears to be essential for this step. This has
been very elegantly shown in zebrafish that develop invasive
melanoma induced by mutant RAS, which is however completely
abolished when RAS is rendered incapable of activating MAPK
signaling (Michailidou et al., 2009). Importantly, these fish do
not even develop nevi, clearly demonstrating that no melanocyte
proliferation had occurred in the absence of constitutive
MAPK signaling, and tumor initiation was completely blocked
(Michailidou et al., 2009).
During the last 14 years numerous studies have established
the relevance of BRAFV600E-induced MAPK signaling for most
aspects of human melanoma development and progression;
this includes proliferation, survival, hypoxia, invasion, and
angiogenesis (Huntington et al., 2004; Karasarides et al., 2004;
Gaggioli et al., 2007; Kumar et al., 2007; Klein et al., 2008;
Johansson et al., 2009).
THE COMPLEXITY OF ERK/MAP-KINASE
SIGNALING IN MELANOMA
The relevance of the MAPK-pathway for melanoma is reflected
in the overall rate of mutations leading to deregulation of
the pathway. These include not only the ∼50% of BRAF
mutations, but also >25% NRAS mutations and ∼14% of
melanomas with mutations in the RAS suppressor NF1
(CancerGenomeAtlasNetwork 2015).
In contrast to BRAF, mutations in the other isoforms, CRAF
and ARAF are rare. This is thought to be due to the more
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FIGURE 1 | MAPK pathway signaling: transient, sustained, and constitutive. (A) In normal melanocytes the ERK/MAPK pathway is governed by G-protein
couple receptor (GPCR) induced cAMP signaling (i.e., MC1R) and receptor tyrosine kinase (RTK) signaling. MC1R signals mainly through BRAF, while CRAF is
inhibited (Busca et al., 2000; Dumaz et al., 2006). All receptors lead to ERK activation, but through the differential induction of the ERK phosphatase DUSP1 (MKP1)
this results in either transient or sustained ERK activation (Wellbrock et al., 2002b). The melanocyte fate regulator MITF is an ERK target and sustained ERK
phosphorylation stimulates its degradation (Wu et al., 2000), which keeps MITF levels low- a state competitive with proliferation. However, cAMP signaling induces
MITF expression and in the absence of active ERK this leads to MITF up-regulation, which triggers differentiation. (B) In Xiphophorus hybrids harboring the
macromelanophore locus Tu-Sd (Tumor-spotted dorsal pattern) in which melanoma development is driven by the melanocyte specific overexpression of the EGFR
homolog Xmrk, ERK is constitutively activated in early benign “nevus”-like lesions and its activation is maintained in malignant melanomas. A phospho-ERK Western
blot of lysates (100 µg total protein) from individual fish carrying either nevi (n = 4) or malignant melanomas (n = 7) is shown. Lysates from A431 cancer cells and from
muscle tissue served as positive and negative control respectively (adapted from Wellbrock and Schartl, 1999).
complex mechanisms underlying activation of these isoforms
(Emuss et al., 2005). As a consequence activation of ARAF
or CRAF would require at least two mutation events, while
the BRAF kinase can be rendered active by one mutation
event. The majority of these mutations affect the phosphate-
binding loop (P-loop) or the activation loop (A-loop) in the
kinase domain (Davies et al., 2002). The most common V600E
substitution mimics phosphorylation of the A-loop, inducing an
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active conformation of the kinase (Wan et al., 2004; Garnett et al.,
2005).
Surprisingly, other mutations were found to render BRAF
inactive (Davies et al., 2002). The biochemical analysis of these
“kinase-impaired” mutations revealed that although they reduce
BRAF’s enzymatic activity, BRAF still activates MEK through
dimerization with CRAF in a RAS dependentmanner (Wan et al.,
2004; Garnett et al., 2005). Confirming earlier studies (Weber
et al., 2001), it is now well established that RAF kinases homo and
hetero-dimerize partly in a RAS dependent manner. Importantly,
these interactions can impact on the response to inhibitors
of BRAF. Thereby, inhibitor-binding triggers dimerization and
in the presence of (hyper)-active RAS, instead of pathway-
inhibition, this leads to the so called “paradoxical” pathway-
activation through CRAF (Wan et al., 2004; Garnett et al.,
2005; Hatzivassiliou et al., 2010; Heidorn et al., 2010; Poulikakos
et al., 2011). Elucidation of this complex mechanism has proven
valuable in the understanding of some of the side effects that
BRAF inhibitors produce in patients (see below).
The MAPK-pathway is not linear but part of a complex
network containing scaffold proteins and feedback loops. The
scaffold protein KSR competes with CRAF for inhibitor-induced
BRAF-binding and can counteract the “paradoxical activation”
of ERK (McKay et al., 2011), but another scaffold protein,
IQGAP promotes ERK activation and the targeted interruption
of its interaction with ERK1/2 can contribute to MAPK-pathway
inhibition (Jameson et al., 2013). Furthermore, complex feedback
loops are induced through the expression of phosphatases (e.g.,
DUSP6) or adaptor proteins (e.g., SPROUTY) (Hanafusa et al.,
2002; Owens and Keyse, 2007). This is also crucial in the context
of BRAF inhibition in patients, where these negative feedback
mechanisms are relieved with the subsequent up-regulation
of other MEK up-stream regulators allowing MAPK pathway
activation without BRAF involvement (Lito et al., 2013).
THE DEVELOPMENT OF BRAF, MEK, AND
ERK INHIBITORS
First attempts to inhibit BRAFV600E in patients using sorafenib
(BAY 43-9006), a broadband kinase inhibitor originally designed
to inhibit CRAF, were rather disappointing (Eisen et al., 2006).
However, between 2011 and 2014 the FDA and the EMA have
approved the use of vemurafenib (PLX4032) and dabrafenib
(GSK2118436) for the treatment of BRAF mutant melanoma
patients. Both, vemurafenib and dabrafenib bind to the active
site in the kinase domain in its “DGF-in” (active) conformation,
thereby blocking the access to ATP, and both inhibitors display
similar potency for BRAFV600E and CRAF and selectivity against
many other kinases (Bollag et al., 2010; Waizenegger et al.,
2016). Phase I to III trials using these drugs showed impressive,
unprecedented clinical responses in the field of targeted therapies
with overall responses of 80%, median progression free survival
between 6 and 9 months and median overall survival rates
between 13 and 19 months (Flaherty et al., 2010; Chapman
et al., 2011; Hauschild et al., 2012; Long et al., 2012; Sosman
et al., 2012). Of note, up to 30% of patients treated with BRAF
inhibitors develop RAS driven cancers such as squamous cell
carcinomas, colon cancer or leukemia (Flaherty et al., 2010;
Chapman et al., 2011; Callahan et al., 2012). These “side-effects”
are most likely due to the “paradoxical” activation of CRAF
in RAF dimers upon inhibitor-binding to wild-type BRAF. As
mentioned before, paradoxical activation of CRAF depends on
active RAS and is thus favored in cells that signal through RAS
(Hatzivassiliou et al., 2010; Heidorn et al., 2010; Poulikakos et al.,
2011).
In parallel, inhibitors targeting MEK (e.g., selumetinib,
trametinib, cobimetinib) have been developed. BRAF’s unique
effector is MEK, and pre-clinical studies have shown that BRAF
mutant cells are significantly more sensitive to MEK inhibition
inhibitors than RAS mutant cells (Solit et al., 2006), probably due
to RAS activating other pathways such as the PI3K-cascade to
promote cell survival (Haass et al., 2008). Despite drug related
toxicities limiting the use of MEK inhibitors, recently developed
highly potent inhibitors show efficacy in patients (Flaherty et al.,
2012; Kirkwood et al., 2012; Ascierto et al., 2013).
Recently, the attention has also moved to ERK and the first
ERK inhibitors that are effective in both, BRAF and NRAS
mutant as well as cells that have developed resistance to MEK
inhibitors have been described (Hatzivassiliou et al., 2012; Morris
et al., 2013). Trials testing SCH772984 and GDC-0994 are
currently ongoing.
MECHANISMS OF RESISTANCE TO BRAF
AND MEK INHIBITORS
Despite the outstanding responses obtained with BRAF
inhibitors, in the majority of patients clinical responses are
transient. The analysis of melanomas from patients relapsed
on BRAF inhibitor treatment revealed the vast complexity of
the MAPK signaling network and over the last years a plethora
of mechanisms have been identified that allow cells to bypass
BRAF inhibition by activating other signaling nodes eventually
re-establishing MEK activity and hence reactivation of ERK [for
a detailed review see Lito et al. (2013)], which is thought to occur
in >70% of patients (Shi et al., 2014; Van Allen et al., 2014).
Some of these mechanisms (Figure 2) involve activating
NRAS mutations or loss of the RAS suppressor NF1 (Whittaker
et al., 2013), BRAF amplification or alternative splicing leading
to BRAF truncations (Poulikakos et al., 2011; Shi et al.,
2012) and overexpression or mutation of the MEK activators
CRAF, COT/TPL2/MAP3K8 or MLKs (Montagut et al., 2008;
Johannessen et al., 2010; Marusiak et al., 2014). BRAF inhibitor
action can also be overcome by mutations in MEK itself, and
while some of these mutations increase the basal kinase activity
of MEK, others render the kinase insensitive to MEK inhibitors
(Emery et al., 2009; Wagle et al., 2011).
Intriguingly, increased receptor tyrosine kinase (RTK)
signaling through for instance IGF-1R, PDGFR, or EGFR is also
frequently found in relapsed melanomas (Nazarian et al., 2010;
Villanueva et al., 2010; Girotti et al., 2013; Sun et al., 2014), and
this can lead to ERK activation via classical pathway activation
through RAS and CRAF (Figure 2). Moreover, RTK signaling
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FIGURE 2 | Resistance mechanisms in MAPK-inhibitor treated melanoma. Resistance to BRAF inhibitors can occur through activating NRAS mutations (*),
loss of the RAS suppressor NF1, BRAF amplification or alternative splicing leading to BRAF truncations (semicircles B*), overexpression or mutation of the MEK
activators CRAF, COT/TPL2/MAP3K8 or MLKs as well as MEK mutations (*). Addition of a MEK inhibitor can buffer some of these resistance mechanisms, but
eventually enhanced resistance signaling will overcome its effects. While ERK is inhibited -particularly in the initial phases of treatment- MITF expression is
up-regulated and contributes to drug-tolerance. Solid arrows indicate signaling induced by mutant BRAF, dashed arrows indicate signaling brought about by the
various resistance mechanisms.
has been linked to an intrinsically BRAF inhibitor resistant
phenotype (Konieczkowski et al., 2014; Muller et al., 2014),
which was unexpected, as RTK signaling was not perceived as
being a major driver of human melanoma. Indeed, it appears
that in heterogeneous tumors RTK-signaling melanoma cells are
present with lower frequency. However, this balance changes
in the presence of a BRAF inhibitor, when RTK-signaling
becomes advantageous (Sun et al., 2014). That RTKs in fact
can be very potent drivers of melanoma development is seen
in Xiphophorus hybrids, where overexpression of an EGFR
homolog stimulates proliferation (Wellbrock et al., 1998) and
is sufficient to initiate and progress melanoma development
(see Figure 1B).
Another BRAF/MEK inhibitor resistance mechanism is based
on overexpression of pro-survival factors that allow melanoma
cells to evade apoptosis even under complete/efficient ERK
inhibition. Around 30% of melanomas display amplifications
in the BLC2A1 gene (Haq et al., 2013). Over-expression of the
anti-apoptotic BLC2A1 protein blocks BRAF and MEK inhibitor
induced apoptosis, and intriguingly, BCL2A1 expression is
regulated by MITF (Haq et al., 2013; Figure 2). This together
with other target genes might underlie the fact that MITF
itself can confer resistance to BRAF and MEK inhibitors even
when ERK is not re-activated (Smith et al., 2013; Muller
et al., 2014). This becomes relevant on the initial phase of
treatment, where (in line with low ERK activity being correlated
with increased MITF levels; see Figure 1A) the majority of
patients show significant up-regulation ofMITF as early response
(Figure 2). Importantly, this increased MITF expression can
contribute to drug-tolerance in the initial phases of treatment
(Smith et al., 2016).
Apart from cell-autonomous resistance, the tumor-stroma
can also confer resistance to BRAF inhibitors (Figure 2).
HGF secreted by stromal fibroblasts can circumvent BRAF
inhibition by re-activating ERK through cMET/RAS/CRAF-
signaling (Straussman et al., 2012) and stromal fibroblasts can
alter the ECM and produce resistance by engaging integrin/FAK
signaling (Hirata et al., 2015). Furthermore, tumor associated
macrophages can induce resistance via the secretion of VEGF
or TNFα (Smith et al., 2014; Wang et al., 2015). Secreted factors
can also support the outgrowth of innate resistant cells that are
otherwise slow cycling (Obenauf et al., 2015).
The above-described examples reflect the complexity of
inhibiting the MAPK-pathway as therapy strategy, because
interfering with this central pathway in vivo will inevitably
have also an effect on non-cancer cells. As a consequence,
it can be expected that the entire tumor microenvironment
will readjust to the condition of reduced MAPK signaling and
establish a new balance that eventually can “buffer” the drug
effect.
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THE FUTURE OF MAPK-PATHWAY
TARGETING DRUGS IN MELANOMA
Resistance through BRAF-inhibitor bypass and the development
of RAS-driven secondary cancers in responses to BRAF
inhibition have prompted the development of combination
therapies with BRAF and MEK inhibitors. These combinations
prolong responses and significantly reduce the appearance
of RAS-driven secondary malignancies, but unfortunately
patients still develop resistance (Larkin et al., 2014; Long
et al., 2015). Nevertheless, BRAF/MEK inhibitor combinations
are now accepted as the standard of care for BRAF-mutant
advanced melanoma and the trametinib/dabrafenib and
cobimetinib/vemurafenib combinations received FDA
approval in 2014 and 2015, respectively. In addition,
drugs targeting both BRAF and CRAF and interfering
with dimerization have been described (Girotti et al.,
2015; Yao et al., 2015), but whether the use of such
inhibitors might increase systemic toxicity will have to be
assessed.
Currently, great effort is put into developing novel
combination strategies to conquer resistance and prolong
responses, and one of the main combination targets for
such an approach is the PI3-kinase pathway (PI3-kinase,
mTOR, AKT). The reason for this is its central role in
melanoma, which is reflected in its frequent deregulation
through mutations (CancerGenomeAtlasNetwork 2015),
and these are found even more frequently in BRAF/MEK
inhibitor resistant tumors (Shi et al., 2014; Van Allen et al.,
2014). Furthermore, PI3-kinase signaling is also activated
downstream of mutant NRAS suggesting possible MEK/PI3-
kinase inhibitor combinations. While pre-clinical studies
provide strong evidence for the rationale of these combinations,
the latest clinical trials show that these combinations are
poorly tolerated and toxicity limits efficacy (Bedard et al., 2015;
Tolcher et al., 2015). Nevertheless, as the PI3-kinase pathway
is central to many cancers the aim is to identify the crucial
-and possibly cancer-specific- nodes within the pathway and
design more specific and potent inhibitors (Kwong and Davies,
2013).
Other combinations (e.g., with RTK-inhibitors) are currently
trialed, and of course it is considered to combineMAPK-pathway
inhibitors with immunotherapies. However, the toxicities
observed in the first attempts demonstrate that we require a
much better understanding of the role of MAPK-signaling in the
context of immunity.
CONCLUSIONS
Over the last 5 years the use of MAPK inhibitors in melanoma
patients and the development of resistance to these drugs has
revealed the vast complexity of MAPK signaling that occurs in a
multicellular organism. However, while the ability of the MAPK
pathway to rewire has so far played against its inhibition, there
might be an opportunity to take advantage of this and target
the rewiring. As such, pre-clinical studies support the concept of
a drug-holiday, where drugs are administered intermittently to
break the rewiring (Das Thakur et al., 2013). Another possibility
is to directly target the “rewired phase.” In this phase, in which
cells display an almost uniform rewiring response and >80% of
tumors react with MITF up-regulation, targeting the rewiring-
mechanism produces impressive responses in pre-clinical studies
(Smith et al., 2016) Thus, with all the excitement about the
latest immunotherapy successes, it should not be forgotten that
BRAF and MEK inhibitors produce immediate and impressive
results and long-lasting (>4 years) responses are also observed
in a number of melanoma patients (Puzanov et al., 2015). This
clearly demonstrates that there is room for further improvement
that will allow building on the remarkable achievements of these
targeted therapies.
AUTHOR CONTRIBUTIONS
CW and IA contributed to the writing of the article.
FUNDING
Work in the laboratory of CW is funded by Cancer Research UK
(grant C11591/A16416).
REFERENCES
Abdel-Malek, Z. A., Kadekaro, A. L., and Swope, V. B. (2010). Stepping up
melanocytes to the challenge of UV exposure. Pigment Cell Melanoma Res. 23,
171–186. doi: 10.1111/j.1755-148X.2010.00679.x
Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C.
M., Queirolo, P., et al. (2013). MEK162 for patients with advanced melanoma
harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label
phase 2 study. Lancet Oncol. 14, 249–256. doi: 10.1016/S1470-2045(13)70024-X
Bedard, P. L., Tabernero, J., Janku, F., Wainberg, Z. A., Paz-Ares, L., Vansteenkiste,
J., et al. (2015). A phase Ib dose-escalation study of the oral pan-PI3K
inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor
trametinib (GSK1120212) in patients with selected advanced solid tumors.Clin.
Cancer Res. 21, 730–738. doi: 10.1158/1078-0432.CCR-14-1814
Bohm, M., Moellmann, G., Cheng, E., Alvarez-Franco, M., Wagner, S., Sassone-
Corsi, P., et al. (1995). Identification of p90RSK as the probable CREB-Ser133
kinase in human melanocytes. Cell Growth Differ. 6, 291–302.
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., et al. (2010). Clinical
efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant
melanoma. Nature 467, 596–599. doi: 10.1038/nature09454
Busca, R., Abbe, P., Mantoux, F., Aberdam, E., Peyssonnaux, C., Eychene, A.,
et al. (2000). Ras mediates the cAMP-dependent activation of extracellular
signal-regulated kinases (ERKs) in melanocytes. EMBO J. 19, 2900–2910. doi:
10.1093/emboj/19.12.2900
Busca, R., and Ballotti, R. (2000). Cyclic AMP a key messenger in the regulation
of skin pigmentation. Pigment Cell Res. 13, 60–69. doi: 10.1034/j.1600-
0749.2000.130203.x
Callahan, M. K., Rampal, R., Harding, J. J., Klimek, V.M., Chung, Y. R., Merghoub,
T., et al. (2012). Progression of RAS-mutant leukemia during RAF inhibitor
treatment. N. Engl. J. Med. 367, 2316–2321. doi: 10.1056/NEJMoa1208958
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P.,
Larkin, J., et al. (2011). Improved survival with vemurafenib in melanoma
with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516. doi:
10.1056/NEJMoa1103782
Frontiers in Cell and Developmental Biology | www.frontiersin.org 6 April 2016 | Volume 4 | Article 33
Wellbrock and Arozarena MAP Kinase Signaling in Melanoma
Cohen, C., Zavala-Pompa, A., Sequeira, J. H., Shoji, M., Sexton, D. G., Cotsonis,
G., et al. (2002). Mitogen-actived protein kinase activation is an early event in
melanoma progression. Clin. Cancer Res. 8, 3728–3733.
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky,W.
E. Jr., et al. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic
melanoma. Nat. Genet. 41, 544–552. doi: 10.1038/ng.356
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K.,
Levesque, M. P., et al. (2013). Modelling vemurafenib resistance in melanoma
reveals a strategy to forestall drug resistance. Nature 494, 251–255. doi:
10.1038/nature11814
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., et al. (2002).
Mutations of the BRAF gene in human cancer. Nature 417, 949–954. doi:
10.1038/nature00766
Dhomen, N., Reis-Filho, J. S., da Rocha Dias, S., Hayward, R., Savage, K., Delmas,
V., et al. (2009). Oncogenic Braf induces melanocyte senescence andmelanoma
in mice. Cancer Cell 15, 294–303. doi: 10.1016/j.ccr.2009.02.022
Dumaz, N., Hayward, R., Martin, J., Ogilvie, L., Hedley, D., Curtin, J. A., et al.
(2006). In melanoma, RAS mutations are accompanied by switching signaling
from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 66,
9483–9491. doi: 10.1158/0008-5472.CAN-05-4227
Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., Marais, R., et al. (2006).
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial
analysis. Br. J. Cancer 95, 581–586. doi: 10.1038/sj.bjc.6603291
Emery, C. M., Vijayendran, K. G., Zipser, M. C., Sawyer, A. M., Niu, L., Kim,
J. J., et al. (2009). MEK1 mutations confer resistance to MEK and B-RAF
inhibition. Proc. Natl. Acad. Sci. U.S.A. 106, 20411–20416. doi: 10.1073/pnas.
0905833106
Emuss, V., Garnett, M., Mason, C., and Marais, R. (2005). Mutations of C-RAF are
rare in human cancer because C-RAF has a low basal kinase activity compared
with B-RAF. Cancer Res. 65, 9719–9726. doi: 10.1158/0008-5472.CAN-05-1683
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A.,
et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma.N.
Engl. J. Med. 363, 809–819. doi: 10.1056/NEJMoa1002011
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., et al.
(2012). Improved survival with MEK inhibition in BRAF-mutated melanoma.
N. Engl. J. Med. 367, 107–114. doi: 10.1056/NEJMoa1203421
Gaggioli, C., Robert, G., Bertolotto, C., Bailet, O., Abbe, P., Spadafora, A., et al.
(2007). Tumor-derived fibronectin is involved in melanoma cell invasion and
regulated by V600E B-Raf signaling pathway. J. Invest. Dermatol. 127, 400–410.
doi: 10.1038/sj.jid.5700524
Garnett, M. J., Rana, S., Paterson, H., Barford, D., andMarais, R. (2005). Wild-type
and mutant B-RAF activate C-RAF through distinct mechanisms involving
heterodimerization.Mol. Cell 20, 963–969. doi: 10.1016/j.molcel.2005.10.022
Girotti, M. R., Lopes, F., Preece, N., Niculescu-Duvaz, D., Zambon, A., Davies,
L., et al. (2015). Paradox-breaking RAF inhibitors that also target SRC are
effective in drug-resistant BRAF mutant melanoma. Cancer Cell 27, 85–96. doi:
10.1016/j.ccell.2014.11.006
Girotti, M. R., Pedersen,M., Sanchez-Laorden, B., Viros, A., Turajlic, S., Niculescu-
Duvaz, D., et al. (2013). Inhibiting EGF receptor or SRC family kinase signaling
overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 3, 158–167.
doi: 10.1158/2159-8290.CD-12-0386
Gray-Schopfer, V. C., Cheong, S. C., Chong, H., Chow, J., Moss, T., Abdel-
Malek, Z. A., et al. (2006). Cellular senescence in naevi and immortalisation in
melanoma: a role for p16? Br. J. Cancer 95, 496–505. doi: 10.1038/sj.bjc.6603283
Haass, N. K., Sproesser, K., Nguyen, T. K., Contractor, R., Medina, C. A.,
Nathanson, K. L., et al. (2008). The mitogen-activated protein/extracellular
signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces
growth arrest in melanoma cells and tumor regression when combined with
docetaxel. Clin. Cancer Res. 14, 230–239. doi: 10.1158/1078-0432.CCR-07-1440
Hanafusa, H., Torii, S., Yasunaga, T., and Nishida, E. (2002). Sprouty1 and
Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway.
Nat. Cell Biol. 4, 850–858. doi: 10.1038/ncb867
Haq, R., Yokoyama, S., Hawryluk, E. B., Jonsson, G. B., Frederick, D. T., McHenry,
K., et al. (2013). BCL2A1 is a lineage-specific antiapoptotic melanoma
oncogene that confers resistance to BRAF inhibition. Proc. Natl. Acad. Sci. U. S.
A. 110, 4321–4326. doi: 10.1073/pnas.1205575110
Hatzivassiliou, G., Liu, B., O’Brien, C., Spoerke, J. M., Hoeflich, K. P., Haverty,
P. M., et al. (2012). ERK inhibition overcomes acquired resistance to MEK
inhibitors.Mol. Cancer Ther. 11, 1143–1154. doi: 10.1158/1535-7163.MCT-11-
1010
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado,
R., et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK
pathway and enhance growth. Nature 464, 431–435. doi: 10.1038/nature08833
Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M.,
et al. (2012). Dabrafenib in BRAF-mutatedmetastatic melanoma: amulticentre,
open-label, phase 3 randomised controlled trial. Lancet 380, 358–365. doi:
10.1016/S0140-6736(12)60868-X
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas,
I., Dhomen, N., et al. (2010). Kinase-dead BRAF and oncogenic RAS
cooperate to drive tumor progression through CRAF. Cell 140, 209–221. doi:
10.1016/j.cell.2009.12.040
Hemesath, T. J., Price, E. R., Takemoto, C., Badalian, T., and Fisher, D. E. (1998).
MAP kinase links the transcription factor Microphthalmia to c-kit signalling in
melanocytes. Nature 391, 298–301. doi: 10.1038/34681
Hirata, E., Girotti, M. R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M.,
et al. (2015). Intravital imaging reveals how BRAF inhibition generates drug-
tolerant microenvironments with high integrin beta1/FAK signaling. Cancer
Cell 27, 574–588. doi: 10.1016/j.ccell.2015.03.008
Hirobe, T. (2011). How are proliferation and differentiation of melanocytes
regulated? Pigment Cell Melanoma Res. 24, 462–478. doi: 10.1111/j.1755-
148X.2011.00845.x
Huntington, J. T., Shields, J. M., Der, C. J., Wyatt, C. A., Benbow, U., Slingluff,
C. L. Jr., et al. (2004). Overexpression of collagenase 1 (MMP-1) is mediated
by the ERK pathway in invasive melanoma cells: role of BRAF mutation
and fibroblast growth factor signaling. J. Biol. Chem. 279, 33168–33176. doi:
10.1074/jbc.M405102200
Jameson, K. L., Mazur, P. K., Zehnder, A. M., Zhang, J., Zarnegar, B., Sage, J.,
et al. (2013). IQGAP1 scaffold-kinase interaction blockade selectively targets
RAS-MAP kinase-driven tumors.Nat. Med. 19, 626–630. doi: 10.1038/nm.3165
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson,
L. A., et al. (2010). COT drives resistance to RAF inhibition through MAP
kinase pathway reactivation. Nature 468, 968–972. doi: 10.1038/nature09627
Johansson, C. C., Egyhazi, S., Masucci, G., Harlin, H., Mougiakakos, D., Poschke,
I., et al. (2009). Prognostic significance of tumor iNOS and COX-2 in
stage III malignant cutaneous melanoma. Cancer Immunol. Immunother. 58,
1085–1094. doi: 10.1007/s00262-008-0631-1
Karasarides, M., Chiloeches, A., Hayward, R., Niculescu-Duvaz, D., Scanlon, I.,
Friedlos, F., et al. (2004). B-RAF is a therapeutic target in melanoma. Oncogene
23, 6292–6298. doi: 10.1038/sj.onc.1207785
Kirkwood, J. M., Bastholt, L., Robert, C., Sosman, J., Larkin, J., Hersey, P.,
et al. (2012). Phase II, open-label, randomized trial of the MEK1/2 inhibitor
selumetinib as monotherapy versus temozolomide in patients with advanced
melanoma. Clin. Cancer Res. 18, 555–567. doi: 10.1158/1078-0432.CCR-1
1-1491
Klein, R. M., Spofford, L. S., Abel, E. V., Ortiz, A., and Aplin, A. E. (2008). B-
RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion
organization.Mol. Biol. Cell 19, 498–508. doi: 10.1091/mbc.E07-09-0895
Konieczkowski, D. J., Johannessen, C. M., Abudayyeh, O., Kim, J. W., Cooper,
Z. A., Piris, A., et al. (2014). A melanoma cell state distinction influences
sensitivity to MAPK pathway inhibitors. Cancer Discov. 4, 816–827. doi:
10.1158/2159-8290.CD-13-0424
Kortylewski, M., Heinrich, P. C., Kauffmann, M. E., Bohm, M., MacKiewicz, A.,
and Behrmann, I. (2001). Mitogen-activated protein kinases control p27/Kip1
expression and growth of humanmelanoma cells. Biochem. J. 357, 297–303. doi:
10.1042/bj3570297
Kumar, S. M., Yu, H., Edwards, R., Chen, L., Kazianis, S., Brafford, P., et al. (2007).
Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in
melanoma. Cancer Res. 67, 3177–3184. doi: 10.1158/0008-5472.CAN-06-3312
Kwong, L. N., and Davies, M. A. (2013). Navigating the therapeutic complexity of
PI3K pathway inhibition in melanoma. Clin. Cancer Res. 19, 5310–5319. doi:
10.1158/1078-0432.CCR-13-0142
Larkin, J., Ascierto, P. A., Dreno, B., Atkinson, V., Liszkay, G., Maio, M., et al.
(2014). Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
N. Engl. J. Med. 371, 1867–1876. doi: 10.1056/NEJMoa1408868
Li, G., Schaider, H., Satyamoorthy, K., Hanakawa, Y., Hashimoto, K., and
Herlyn, M. (2001). Downregulation of E-cadherin and Desmoglein 1 by
Frontiers in Cell and Developmental Biology | www.frontiersin.org 7 April 2016 | Volume 4 | Article 33
Wellbrock and Arozarena MAP Kinase Signaling in Melanoma
autocrine hepatocyte growth factor during melanoma development. Oncogene
20, 8125–8135. doi: 10.1038/sj.onc.1205034
Lister, J. A., Capper, A., Zeng, Z., Mathers, M. E., Richardson, J., Paranthaman, K.,
et al. (2014). A conditional zebrafish MITF mutation reveals MITF levels are
critical for melanoma promotion vs. regression in vivo. J. Invest. Dermatol. 134,
133–140. doi: 10.1038/jid.2013.293
Lito, P., Rosen, N., and Solit, D. B. (2013). Tumor adaptation and resistance to RAF
inhibitors. Nat. Med. 19, 1401–1409. doi: 10.1038/nm.3392
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin,
J., et al. (2015). Dabrafenib and trametinib versus dabrafenib and placebo
for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase
3 randomised controlled trial. Lancet 386, 444–451. doi: 10.1016/S0140-
6736(15)60898-4
Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman,
P. B., et al. (2012). Dabrafenib in patients with Val600Glu or Val600Lys
BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre,
open-label, phase 2 trial. Lancet Oncol. 13, 1087–1095. doi: 10.1016/S1470-
2045(12)70431-X
Marusiak, A. A., Edwards, Z. C., Hugo, W., Trotter, E. W., Girotti, M.
R., Stephenson, N. L., et al. (2014). Mixed lineage kinases activate MEK
independently of RAF to mediate resistance to RAF inhibitors. Nat. Commun.
5, 3901. doi: 10.1016/s0959-8049(14)70202-3
McKay, M. M., Ritt, D. A., and Morrison, D. K. (2011). RAF inhibitor-induced
KSR1/B-RAF binding and its effects on ERK cascade signaling. Curr. Biol. 21,
563–568. doi: 10.1016/j.cub.2011.02.033
Michailidou, C., Jones, M., Walker, P., Kamarashev, J., Kelly, A., and Hurlstone,
A. F. (2009). Dissecting the roles of Raf- and PI3K-signalling pathways in
melanoma formation and progression in a zebrafish model. Dis. Model. Mech.
2, 399–411. doi: 10.1242/dmm.001149
Michaloglou, C., Vredeveld, L. C., Soengas, M. S., Denoyelle, C., Kuilman, T., van
der Horst, C. M., et al. (2005). BRAFE600-associated senescence-like cell cycle
arrest of human naevi. Nature 436, 720–724. doi: 10.1038/nature03890
Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus,
L. E., et al. (2008). Elevated CRAF as a potential mechanism of acquired
resistance to BRAF inhibition in melanoma. Cancer Res. 68, 4853–4861. doi:
10.1158/0008-5472.CAN-07-6787
Morris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., et al.
(2013). Discovery of a novel ERK inhibitor with activity in models of acquired
resistance to BRAF and MEK inhibitors. Cancer Discov. 3, 742–750. doi:
10.1158/2159-8290.CD-13-0070
Muller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., et al. (2014).
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in
melanoma. Nat. Commun. 5, 5712. doi: 10.1038/ncomms6712
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., et al. (2010).
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS
upregulation. Nature 468, 973–977. doi: 10.1038/nature09626
Obenauf, A. C., Zou, Y., Ji, A. L., Vanharanta, S., Shu, W., Shi, H., et al.
(2015). Therapy-induced tumour secretomes promote resistance and tumour
progression. Nature 520, 368–372. doi: 10.1038/nature14336
Owens, D. M., and Keyse, S. M. (2007). Differential regulation of MAP kinase
signalling by dual-specificity protein phosphatases. Oncogene 26, 3203–3213.
doi: 10.1038/sj.onc.1210412
Patton, E. E., Widlund, H. R., Kutok, J. L., Kopani, K. R., Amatruda, J. F., Murphey,
R. D., et al. (2005). BRAF mutations are sufficient to promote nevi formation
and cooperate with p53 in the genesis of melanoma. Curr. Biol. 15, 249–254.
doi: 10.1016/j.cub.2005.01.031
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M.,
et al. (2003). High frequency of BRAF mutations in nevi. Nat. Genet. 33, 19–20.
doi: 10.1038/ng1054
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G.,
et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly
spliced BRAF(V600E). Nature 480, 387–390. doi: 10.1038/nature10662
Price, E. R., Horstmann, M. A., Wells, A. G., Weilbaecher, K. N., Takemoto, C. M.,
Landis, M. W., et al. (1998). Alpha-melanocyte-stimulating hormone signaling
regulates expression of microphthalmia, a gene deficient in Waardenburg
syndrome. J. Biol. Chem. 273, 33042–33047. doi: 10.1074/jbc.273.49.33042
Puzanov, I., Amaravadi, R. K., McArthur, G. A., Flaherty, K. T., Chapman,
P. B., Sosman, J. A., et al. (2015). Long-term outcome in BRAF(V600E)
melanoma patients treated with vemurafenib: patterns of disease progression
and clinical management of limited progression. Eur. J. Cancer 51, 1435–1443.
doi: 10.1016/j.ejca.2015.04.010
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., et al. (2014).
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor
therapy. Cancer Discov. 4, 80–93. doi: 10.1158/2159-8290.CD-13-0642
Shi, H., Moriceau, G., Kong, X., Lee, M. K., Lee, H., Koya, R. C., et al. (2012).
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-
mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3, 724. doi:
10.1038/ncomms1727
Smith, M. P., Brunton, H., Rowling, E. J., Ferguson, J., Arozarena, A., Miskolczi,
Z., et al. (2016). Inhibiting drivers of non-mutational drug-tolerance is a
salvage strategy for targeted melanoma therapy. Cancer Cell 29, 270–284. doi:
10.1016/j.ccell.2016.02.003
Smith, M. P., Ferguson, J., Arozarena, I., Hayward, R., Marais, R., Chapman, A.,
et al. (2013). Effect of SMURF2 targeting on susceptibility to MEK inhibitors in
melanoma. J. Natl. Cancer Inst. 105, 33–46. doi: 10.1093/jnci/djs471
Smith, M. P., Sanchez-Laorden, B., O’Brien, K., Brunton, H., Ferguson, J., Young,
H., et al. (2014). The immune microenvironment confers resistance to MAPK
pathway inhibitors through macrophage-derived TNFalpha. Cancer Discov. 4,
1214–1229. doi: 10.1158/2159-8290.CD-13-1007
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., et al.
(2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature 439,
358–362. doi: 10.1038/nature04304
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S.,
et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with
vemurafenib. N. Engl. J. Med. 366, 707–714. doi: 10.1056/NEJMoa1112302
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., et al.
(2012). Tumour micro-environment elicits innate resistance to RAF inhibitors
through HGF secretion. Nature 487, 500–504. doi: 10.1038/nature11183
Sun, C., Wang, L., Huang, S., Heynen, G. J., Prahallad, A., Robert, C., et al. (2014).
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Nature 508, 118–122. doi: 10.1038/nature13121
Tolcher, A. W., Patnaik, A., Papadopoulos, K. P., Rasco, D. W., Becerra, C. R.,
Allred, A. J., et al. (2015). Phase I study of the MEK inhibitor trametinib
in combination with the AKT inhibitor afuresertib in patients with solid
tumors and multiple myeloma. Cancer Chemother. Pharmacol. 75, 183–189.
doi: 10.1007/s00280-014-2615-5
Van Allen, E. M., Wagle, N., Sucker, A., Treacy, D. J., Johannessen, C. M., Goetz, E.
M., et al. (2014). The genetic landscape of clinical resistance to RAF inhibition
inmetastatic melanoma.Cancer Discov. 4, 94–109. doi: 10.1158/2159-8290.CD-
13-0617
Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M.,
Cipolla, A. K., et al. (2010). Acquired resistance to BRAF inhibitors mediated
by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and
IGF-1R/PI3K. Cancer Cell 18, 683–695. doi: 10.1016/j.ccr.2010.11.023
Viros, A., Sanchez-Laorden, B., Pedersen, M., Furney, S. J., Rae, J., Hogan, K.,
et al. (2014). Ultraviolet radiation accelerates BRAF-driven melanomagenesis
by targeting TP53. Nature 511, 478–482. doi: 10.1038/nature13298
Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard,
P., et al. (2011). Dissecting therapeutic resistance to RAF inhibition in
melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085–3096. doi:
10.1200/JCO.2010.33.2312
Waizenegger, I. C., Baum, A., Steurer, S., Stadtmuller, H., Bader, G., Schaaf, O.,
et al. (2016). A Novel RAF Kinase Inhibitor with DFG-out-binding mode: high
efficacy in BRAF-mutant tumor xenograft models in the absence of normal
tissue hyperproliferation. Mol. Cancer Ther. 15, 354–365. doi: 10.1158/1535-
7163.MCT-15-0617
Wan, P. T., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V.
M., et al. (2004). Mechanism of activation of the RAF-ERK signaling pathway
by oncogenic mutations of B-RAF. Cell 116, 855–867. doi: 10.1016/S0092-
8674(04)00215-6
Wang, T., Xiao, M., Ge, Y., Krepler, C., Belser, E., Lopez-Coral, A., et al.
(2015). BRAF inhibition stimulates melanoma-associatedmacrophages to drive
tumor growth. Clin. Cancer Res. 21, 1652–1664. doi: 10.1158/1078-0432.CCR-
14-1554
Weber, C. K., Slupsky, J. R., Kalmes, H. A., and Rapp, U. R. (2001). Active Ras
induces heterodimerization of cRaf and BRaf. Cancer Res. 61, 3595–3598.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 8 April 2016 | Volume 4 | Article 33
Wellbrock and Arozarena MAP Kinase Signaling in Melanoma
Wellbrock, C., and Arozarena, I. (2015). Microphthalmia-associated transcription
factor in melanoma development and MAP-kinase pathway targeted therapy.
Pigment Cell Melanoma Res. 28, 390–406. doi: 10.1111/pcmr.12370
Wellbrock, C., Fischer, P., and Schartl, M. (1998). Receptor tyrosine kinase Xmrk
mediates proliferation in xiphophorus melanoma cells. Int. J. Cancer 76,
437–442.
Wellbrock, C., Gomez, A., and Schartl, M. (2002a). Melanoma development and
pigment cell transformation in xiphophorus. Microsc. Res. Tech. 58, 456-463.
doi: 10.1002/jemt.10163
Wellbrock, C., and Marais, R. (2005). Elevated expression of MITF counteracts B-
RAF-stimulated melanocyte and melanoma cell proliferation. J. Cell Biol. 170,
703–708. doi: 10.1083/jcb.200505059
Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-
Duvaz, D., et al. (2004). V599EB-RAF is an Oncogene in melanocytes. Cancer
Res. 64, 2338–2342. doi: 10.1158/0008-5472.CAN-03-3433
Wellbrock, C., Rana, S., Paterson, H., Pickersgill, H., Brummelkamp, T., and
Marais, R. (2008). Oncogenic BRAF regulates melanoma proliferation
through the lineage specific factor MITF. PLoS ONE 3:e2734. doi:
10.1371/journal.pone.0002734
Wellbrock, C., and Schartl, M. (1999). Multiple binding sites in the growth factor
receptor Xmrk mediate binding to p59fyn, GRB2 and Shc. Eur. J. Biochem. 260,
275–283. doi: 10.1046/j.1432-1327.1999.00180.x
Wellbrock, C., Weisser, C., Geissinger, E., Troppmair, J., and Schartl, M. (2002b).
Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing
MKP-1-regulated mitogen-activated protein kinase signaling. J. Biol. Chem.
277, 6443–6454. doi: 10.1074/jbc.M110684200
Whittaker, S. R., Theurillat, J. P., Van Allen, E., Wagle, N., Hsiao, J., Cowley, G.
S., et al. (2013). A genome-scale RNA interference screen implicates NF1 loss
in resistance to RAF inhibition. Cancer Discov. 3, 350–362. doi: 10.1158/2159-
8290.CD-12-0470
Wu, M., Hemesath, T. J., Takemoto, C. M., Horstmann, M. A., Wells, A. G.,
Price, E. R., et al. (2000). c-Kit triggers dual phosphorylations, which couple
activation and degradation of the essential melanocyte factorMi.Genes Dev. 14,
301–312. doi: 10.1101/gad.14.3.301
Yao, Z., Torres, N. M., Tao, A., Gao, Y., Luo, L., Li, Q., et al. (2015). BRAF mutants
evade ERK-dependent feedback by different mechanisms that determine
their sensitivity to pharmacologic inhibition. Cancer Cell 28, 370–383. doi:
10.1016/j.ccell.2015.08.001
Zeng, Z., Johnson, S. L., Lister, J. A., and Patton, E. E. (2015). Temperature-
sensitive splicing of mitfa by an intron mutation in zebrafish. Pigment Cell
Melanoma Res. 28, 229–232. doi: 10.1111/pcmr.12336
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Wellbrock and Arozarena. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 9 April 2016 | Volume 4 | Article 33
